International Myeloma Working Group Conference Series
Milan, Italy | June 11, 2014
Novel Agents and Best Treatment Choices for Transplant Eligible Patients
Novel Agents and Best Treatment Choices for Transplant-Ineligible Patients
What Are the Pros and Cons of Continuous Therapy?
Minimal Residual Disease (MRD): Can We Use the Information Clinically?
New Promising Therapies Presented at ASH/ASCO/IMWG/EHA